Pfizer receives EC approval for Hympavzi to treat haemophilia
The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or
Inovio has secured accelerated approval from the US Food and Drug Administration (FDA) for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).